Immunotherapy drug delays onset of Type 1 diabetes in at-risk group
More than five years after receiving an experimental immunotherapy drug, half of a group of people at high risk of developing Type 1 diabetes remained disease-free compared with 22% of those who received a placebo, according ...
Mar 3, 2021
0
52